KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Enterprise Value (2016 - 2025)

Alnylam Pharmaceuticals' Enterprise Value history spans 17 years, with the latest figure at -$1.7 billion for Q4 2025.

  • For Q4 2025, Enterprise Value rose 38.31% year-over-year to -$1.7 billion; the TTM value through Dec 2025 reached -$1.7 billion, up 38.31%, while the annual FY2025 figure was -$1.7 billion, 38.31% up from the prior year.
  • Enterprise Value reached -$1.7 billion in Q4 2025 per ALNY's latest filing, up from -$2.7 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$436.5 million in Q1 2021 to a low of -$2.7 billion in Q3 2025.
  • Average Enterprise Value over 5 years is -$1.6 billion, with a median of -$1.8 billion recorded in 2021.
  • The largest YoY upside for Enterprise Value was 66.53% in 2021 against a maximum downside of 336.06% in 2021.
  • A 5-year view of Enterprise Value shows it stood at -$2.4 billion in 2021, then surged by 62.18% to -$896.7 million in 2022, then crashed by 170.8% to -$2.4 billion in 2023, then fell by 10.63% to -$2.7 billion in 2024, then surged by 38.31% to -$1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Enterprise Value are -$1.7 billion (Q4 2025), -$2.7 billion (Q3 2025), and -$1.1 billion (Q2 2025).